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Abstract
KIT receptor tyrosine kinase is expressed in tumor endothelial cells of adult glioblastomas,
butitsexpressioninpediatricbraintumorendothelialcellsisunknown.Weassessedexpres-
sion of KIT, phosphorylated KIT, stem cell factor (SCF) and vascular endothelial growth
factor receptor-2 (VEGFR-2) in 35 juvenile pilocytic astrocytomas and 49 other pediatric
brain tumors using immunohistochemistry, and KIT messenger RNA (mRNA) using in situ
hybridization. KIT and phospho-KIT were moderately or strongly expressed in tumor
endothelia of 37% and 35% of pilocytic astrocytomas, respectively, whereas marked SCF
and VEGFR-2 expression was uncommon. KIT mRNA was detected in tumor endothelial
cells.Tumor endothelial cell KIT expression was strongly (P < 0.01) associated with endot-
helial cell phospho-KIT and SCF expression, and with tumor KIT (P = 0.0011) and
VEGFR-2 expression (P = 0.022). KIT and phospho-KIT were present in endothelia of
other pediatric brain tumors, notably ependymomas. Endothelial cell KIT expression was
associated with a young age at diagnosis of pilocytic astrocytoma or ependymoma, and it
was occasionally present in histologically normal tissue of the fetus and children. We
conclude that KIT is commonly present in endothelial cells of juvenile brain tumors and
thus may play a role in angiogenesis in these neoplasms.
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INTRODUCTION
KIT tyrosine kinase is a member of the platelet-derived growth
factor receptor (PDGFR) subfamily III of receptor tyrosine kinases
(17,28).KITbindsspeciﬁcallystemcellfactor(SCF),whichexists
both as soluble and membrane-bound forms (1, 9, 15). Both KIT
andSCFareexpressedinawidevarietyoftissuesinthedeveloping
embryo and throughout the postnatal life, and are involved in
numerous functions (3). In the nervous system KIT and SCF are
expressed in the olfactory bulb, the cerebral cortex, the hippocam-
pus, the cerebellum and in the spinal cord (8, 17, 27). Recombinant
SCF induces neurite outgrowth from the dorsal root ganglia, where
KIT-positiveneuronscanbedetectedalreadyduringtheembryonic
development and where its expression persists throughout the
postnatal period (7). KIT mutations are associated with some adult
cancers, notably gastrointestinal stromal tumors (GISTs; 6, 12, 18,
20).
Recent ﬁndings suggest that the SCF/KIT signaling plays an
important role in angiogenesis of brain tumors and also of histo-
logically normal tissues (24). SCF activates brain microvascular
endothelial cells in vitro by enhancing proliferation, survival and
migration of the endothelial cells. Tumor cells with the strongest
SCF expression as well as normal SCF-expressing neurons are
found predominantly within the inﬁltrating tumor border where
angiogenesis is prominent (24). Moderate or strong expression of
KIT and phosphorylated (activated) KIT have been detected in
tumor endothelial cells of glioblastomas, but only infrequently in a
few other histological types of human cancer (21). Signaling via
KIT presumably enhances the umbilical vein endothelial cell tube
formation, and increases endothelial cell survival in vitro (14).
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may have a role in angiogenesis of brain tumors, and possibly of
other types of human tumors and normal tissues as well.
Some pediatric tumors express KIT (2, 23), but little is known
about expression or the role of endothelial cell KIT in pediatric
brain tumors (21). In the present study we investigated expression
of tumor and intratumoral vessel endothelial cell KIT, SCF and
vascular endothelial cell growth factor receptor-2 (VEGFR-2) in
pilocytic astrocytomas and other pediatric brain tumors.
PATIENTS AND METHODS
Tissue samples
Formalin-ﬁxed, parafﬁn-embedded tissues were retrieved from 35
juvenile pilocytic astrocytomas diagnosed at the age of 18 or
younger at the Helsinki University Central Hospital (HUCH), Hel-
sinki, Finland, in 1985 to 2007, for analysis. The patients were not
consecutive, but were selected at random.The median age at diag-
nosis was 10 years (range 0 to 18), and 18 (51%) were male. Most
(62%) tumors were conﬁned to the cerebellum and were treated
withsurgery.Themedianfollow-uptimeofthepatientswas5years
(range 0 to 18 years) after the diagnosis. Seven of the tumors
recurred, but only one patient died during the follow-up.
Besides pilocytic astrocytomas, we examined 49 pediatric
brain tumors of various histological types (11 ependymomas, 12
medulloblastomas, 7 dysembryoblastic neuroepithelial tumors, 4
gangliogliomas and 15 tumors of other histological type). These
tumorswerediagnosedwithinthesametimeperiodandatthesame
institute, and were also selected for analysis at random.The tumor
diagnoseswerereviewedbyprofessionalpathologists(OTynninen,
A Paetau) according to the World Health Organization (WHO)
classiﬁcation (13).
To examine vascular endothelial cell KIT expression during the
fetal life and during childhood, histologically normal parafﬁn-
embedded tissue samples from several organs were collected for
analysis. The fetal samples were obtained from a fetus aborted at
the gestational age of 18 weeks (n = 2) or from an autopsy per-
formed due to a stillbirth at the gestational age of 23 weeks and 40
weeks (n = 4). Histologically normal tissue samples (n = 2) were
also obtained from an autopsy of a young child who died at the age
of 18 months, and from non-tumoral brain tissue of eight children,
who underwent surgery to remove epileptogenic focal cortical dys-
plasia(ageatthetimeofsurgerywas3,4,8,9,10,14and15years).
ThestudyprotocolwasapprovedbyInstitutionalReviewBoards
ofHelsinkiandTurkuUniversityHospitals,andapermissiontouse
the tissue sections for the study was provided by the National
Authority for MedicolegalAffairs of Finland.
Immunohistochemistry
Five-micrometer whole tumor tissue sections were cut from repre-
sentative formalin-ﬁxed, parafﬁn-embedded tissue blocks. The
tissue sections were stained for KIT, phosphorylated KIT, SCF,
hypoxia-induced factor-1a (HIF-1a), and VEGFR-2 expression
using immunohistochemistry as described elsewhere (21). KIT
was stained with a rabbit polyclonal anti-CD117 antibody (dilu-
tion, 1:300; A 4502, DAKO, Glostrup, Denmark), phosphorylated
KIT with a polyclonal rabbit anti-phospho-KIT antibody (#3391;
1:35; directed at the Tyr719 residue that mediates activation of the
phosphatidyl inositiol 3-kinase (PI3K)/ Akt pathway; Cell Signal-
ingTechnology, Inc, Danvers, MA, USA), SCF with a monoclonal
mouseanti-SCFantibody(1:200,hKL12;AcrisAntibodiesGmbH,
Hiddenhausen, Germany), HIF-1a with a monoclonal mouse anti-
HIF-1a antibody (1:100, H1alpha67,Ab-4; Neomarkers, Fremont,
CA, USA), and VEGFR-2 with an epitope-speciﬁc rabbit anti-
VEGFR-2 antibody (Flk-1 Ab-1, NeoMarkers, Lab Vision
Corp., Fremont, CA, USA). The antibodies were diluted into a
PowerVision preantibody blocking solution and were incubated
with the sample.The binding of the primary antibody was detected
withaPowervision+Poly-HRPhistostainingkit(DPVB+110DAB,
ImmunoVision Technologies Co., Daly City, CA). The tissue sec-
tions were counterstained with hematoxylin & eosin.
Mast cells (which are strongly KIT-positive) were used as inter-
nal controls, and primary glioblastomas with a known expression
of endothelial cell KIT, phosphorylated KIT, and tumor cell or
perinecrotic expression of HIF-1a and SCF were used as positive
controls in immunohistochemical staining (21). In addition, histo-
logically normal bone marrow was used as a positive control in
immunostaining for SCF and wound tissue forVEGFR-2. Immun-
ostaining of the tumors was graded as negative (-), faintly positive
(+), moderately positive (++) or strongly positive (+++) by a pro-
fessional pathologist (O Tynninen) and one of the authors (M
Puputti) using a consultation microscope (Nikon Eclipse E600,
Nikon Instech Co., Ltd., Kanagawa, Japan).Tumor endothelial cell
KIT expression was considered either negative (-), faintly positive
(+) when 1% to 10% of the intratumoral vessels were positive,
markedly positive (++) when 11% to 50% of the intratumoral
vessels stained positively, and strongly positive when over 50% of
the intratumoral vessels were positive (Figure 1A–C).
mRNA in situ hybridization for KIT
Digoxigenin-labelled locked nucleic acid probes (LNATM mRNA,
Exiqon, Inc., Woburn, MA, USA) were designed against the KIT
extracellular domain coding sequences 5′-gttgagaagagcctgtct
ggac-3′ and 5′-cttggcaggatctctaacaaacacat-3′. Efﬁcacy of hybrid-
izationwascontrolledwithapolyT(25)Vnprobe(LNATM,Exiqon)
against the poly(A) tail. In situ hybridization was carried out on
whole deparafﬁnized tissue sections as described earlier with
minor modiﬁcations (21).All reagents and instruments were either
treated with diethyl pyrocarbonate (DEPC) or were made RNAse-
free. The tissue sections were counterstained with 0.1% Nuclear
Fast Red (Sigma-Aldrich Inc., St. Louis, MO, USA). The hybrid-
ization results were graded either as negative (-) or positive (+).
Glioblastomas with a known endothelial cell KIT expression in the
tumor vasculature served as positive controls (21).
Chromogenic in situ hybridization (CISH)
CISH was performed as described elsewhere (25). In brief, 3-mm-
thick whole tissue sections mounted on glass slides were deparaf-
ﬁnized and heat-pretreated in a temperature-controlled microwave
oven.Bacterialartiﬁcialclone(BAC)probesforKITwereprepared
as described elsewhere (11), and applied onto the slides. The sec-
tions were denatured in the presence of the BAC probes on a heat
plate, and hybridization was expected to occur during an overnight
incubation at +37°C. The signals were detected with a Spot-Light
CISH detection kit (Zymed, Inc., South San Francisco, CA, USA)
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deﬁned to be present when 6 or more signals, or clusters of signals,
were detected in one nucleus in more than 10% of the counted
nuclei. Endothelial cells within the tumor sections showed a
diploid copy number in each case, and served as internal controls
for hybridization.
Statistical analysis
Frequency tables were analyzed using Fisher’s exact test. When
examining associations between tumor endothelial cell KIT,
phosphorylated KIT and VEGFR-2, tumors with moderate
(++) or strong (+++) expression in endothelial cells were
grouped together and compared with those with either
negative (-) or faint (+) expression. Tumor KIT, phospho-KIT
and SCF expression was classiﬁed either as positive (+, ++
or +++)o rn e g a t i v e( -) in statistical calculations. Non-normal
distributions between the groups were compared using the
Kruskal–Wallis or the Mann–Whitney test. Life tables were con-
structed using the Kaplan–Meier method, and survival between
groups was compared using the log-rank test. The P values are
two-sided.
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Figure 1. Faint (+, A), moderate (++, B) and
strong (+++, C) expression of endothelial cell
KIT in pediatric pilocytic astrocytomas (original
magniﬁcation ¥200, A; and ¥400, B,C). A
vascular proliferation with multiple lumens is
shown in C. (D) Endothelial cell expression of
phosphorylated KIT in pilocytic astrocytoma
(+++; ¥200). (E) KIT mRNA in endothelial cells
(arrowheads) of pilocytic astrocytoma
detected by in situ hybridization (¥1000). (F)
Faint (+) SCF expression in pilocytic
astrocytoma (¥400). (G) Moderate (++)
expression of VEGFR-2 in astrocytoma tumor
cells (¥400). (H) Brain endothelial cells
showing moderate expression of
phosphorylated KIT in a 18-week-old fetus
(¥200, arrows).
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Expression of KIT, SCF and VEGFR-2 in
pilocytic astrocytomas
When endothelial cells (cells that lined the capillary lumens)
stained positively for KIT, both delicate capillaries with ﬂat endot-
helium and aggregations of vessels with hypertrophic and plump
endothelial cells stained positively (Figure 1A–C). Moderate (++)
or strong (+++) KIT expression was detected in tumor endothelial
cells in 13 (37%) out of the 35 juvenile pilocytic astrocytomas,
whereas in none of the cases the tumor cells expressed KIT at these
levels (Figure 1A–C; Table 1).Vascular hyperplasia was present in
13(37%)tumors(Figure 1C).Six(46%)ofthesetumorsexpressed
KIT moderately strongly or strongly in endothelial cells of the
vascular proliferations. Six (46%) out of the 13 tumors with vascu-
lar proliferations expressed KIT also in the ﬂat endothelial cells
compared with 7 (32%) out of the 22 tumors that lacked vascular
hyperplasia (P = 0.48). Nonspeciﬁc staining of proteins in the
vessel lumen was not detected, and abluminal cells (pericytes) did
not stain for KIT.
Staining for phosphorylated KIT was present both in delicate
capillaries and hypertrophic vessels with no apparent association
between phosphorylated KIT immunoexpression and microvessel
morphology (Figure 1D). Phosphorylated KIT was moderately
(++)orstrongly(+++)expressedinendotheliaof10(29%)tumors,
but it was not expressed strongly in any of the cases in tumor cells.
In contrast, moderate or strong SCF or VEGFR-2 expression was
not detected in pilocytic astrocytoma endothelial cells [SCF was
expressed weakly in 7 (23%) out of the 31 assessable tumors],
whereas 6 (19%) tumors expressedVEGFR-2 moderately (++).
KIT mRNA in endothelial cells
We used in situ hybridization to study presence of messenger RNA
(mRNA) in the endothelial cells of 19 pilocytic astrocytomas. KIT
mRNA was detected in the endothelial cells of 5 (26%) tumors.
Four of these ﬁve tumors showed moderate or strong endothelial
cell KIT expression in immunohistochemistry (Figure 1E).
Copy number analysis of KIT gene
KIT gene copy number was assessed using CISH in 9 pilocytic
astrocytomas. None of the tumors had ampliﬁcation of the gene.
Two tumors showed KIT aneuploidy (three to ﬁve KIT gene copies
were present per one cell).
Associations between endothelial cell and tumor cell
KIT, SCF and VEGFR-2 expression
Tumor endothelial cell KIT expression was highly signiﬁcantly
associated with endothelial cell phospho-KIT expression
(P = 0.0009), suggesting that endothelial cell KIT was often acti-
vated. Endothelial cell KIT was also associated with endothelial
cell SCF expression (P = 0.0017), but not with endothelial cell
VEGFR-2 expression (P = 0.35, a representative staining shown in
Figures 1F and G). Endothelial cell expression of phosphorylated
KIT was associated with endothelial cell SCF expression
(P = 0.0002), but neither endothelial cell phosphorylated KIT nor
SCF expression was associated with endothelial cell VEGFR-2
expression (P = 0.62 and 0.57, respectively).
Pilocytic astrocytomas that expressed KIT in tumor cells
expressed frequently KIT, phospho-KIT and SCF in the tumor
microvessel endothelial cells as well, but not endothelial cell
VEGFR-2 (Table 2). Tumor cell phospho-KIT expression was
associated with endothelial cell KIT expression (P = 0.011), and
tumor cell SCF expression with endothelial cell SCF expression
(P = 0.029). Pilocytic astrocytomas that expressed VEGFR-2
expressed often endothelial cell KIT (P = 0.022) and phospho-KIT
(P = 0.049), and tended to express SCF in the tumor endothelial
cells (P = 0.077).
HIF-1a was evaluated in tumor cells and perinecrotic areas.
HIF-1awaspresentonlyin3(9%)outofthe32evaluatedpilocytic
astrocytomas, and its expression was faint (+) in all these cases.
Two pilocytic astrocytomas contained necrotic areas, and HIF-1a
waspresentintheperinecrotictumorcellsinbothcasesatafaintor
moderate intensity.
Tumor endothelial cell KIT, age at diagnosis
and survival
A strong association was found between age at diagnosis and
KIT expression in the endothelial cells of pilocytic astrocytomas.
Patients diagnosed at a young age with pilocytic astrocytoma
usually had moderate or strong tumor endothelial cell KIT expres-
sion, whereas those diagnosed at an older age had no or only faint
KITexpressioninthetumorendothelialcells(Kruskall–Wallistest
P = 0.0012, Figure 2, upper panel; when analyzed moderate or
Table 1. Expression of KIT, phosphorylated KIT, SCF, and VEGFR-2 in
juvenile pilocytic astrocytomas. Abbreviations: N = number of cases;
SCF = the stem cell factor; VEGFR-2 = vascular endothelial cell growth
factor receptor-2.
Protein Tumor endothelial cell expression
N
-/+/++/+++
Tumor cell Expression
N
-/+/++/+++
KIT 12/10/6/7 29/6/0/0
phospho-KIT 16/8/4/6* 30/4/0/0*
SCF 24/7/0/0** 24/6/1/0**
VEGFR-2 26/5/0/0** 10/15/6/0**
*Staining of one tumor was considered uninformative.
**Staining of four tumors were considered uninformative or adequate
tissue was not available.
Table 2. Associations between tumor cell and tumor endothelial cell
expression of KIT, phosphorylated KIT, SCF and VEGFR-2 in juvenile
pilocytic astrocytomas. Abbreviations: SCF = the stem cell factor;
VEGFR-2 = vascular endothelial cell growth factor receptor-2.
Tumor cell expression Tumor endothelial cell expression
KIT phospho-KIT SCF VEGFR-2
P* P* P* P*
KIT 0.0011 0.019 0.0078 1.0
phospho-KIT 0.011 0.07 0.41 1.0
SCF 0.65 0.33 0.029 0.21
VEGFR-2 0.022 0.049 0.077 0.24
*Fisher’s exact test.
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Whitney test P = 0.0001). A similar association between age at
diagnosis and endothelial cell phospho-KIT expression was also
present (P = 0.048, Mann–Whitney test). Neither endothelial cell
KIT nor phospho-KIT expression was signiﬁcantly associated with
recurrence-free survival in the present series (P = 0.84 and 0.09,
respectively).
Tumor endothelial cell KIT, phospho-KIT and KIT mRNA
in other histological types of pediatric brain tumors
To investigate whether tumor endothelial cells might express KIT,
SCF or VEGFR-2 also in other types of pediatric brain tumors
than pilocytic astrocytoma, we examined 49 further tumors with
immunohistochemistry (Tables 3 and 4). Marked (++ or +++)
expression of KIT and phospho-KIT were frequently present in
the endothelia of ependymomas [6 (55%) out of 11, and 5 (45%)
outof11,respectively].Anaplasticependymomashadglomeruloid
microvascular proliferations resembling those seen in glioblasto-
mas. Staining for KIT was positive in the endothelial cell cyto-
plasm of delicate capillaries (Figure 3A) and microvascular prolif-
erations (Figure 3B). Occasional abluminal cells stained positively
for KIT in the microvascular proliferations, although the staining
intensity was lower than in endothelial cells lining the vessel
lumens (Figure 3B). In anaplastic ependymomas endothelial cells
and most of the abluminal cells of microvascular proliferations
stained positively for phosphorylated KIT with uniform intensity
(Figure 3C).Age at diagnosis and KIT expression in tumor endot-
helial cells had a similar association in ependymomas as in pilo-
cytic astrocytomas, although this association was not statistically
signiﬁcant (P = 0.067, Mann–Whitney test; P = 0.33 Kruskal–
Wallis test; Figure 2, lower panel).
When KIT mRNA expression was studied from seven ependy-
momas using mRNA in situ hybridization (4 of the 11 cases were
uninformative), KIT mRNA was present in 6 (86%) cases in the
tumor vessels. Four of the six ependymomas with KIT mRNA
detected by in situ hybridization expressed endothelial cell KIT
either moderately (++) or strongly (+++) in immunohistochemistry
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Figure 2. Association between age at diagnosis and endothelial cell
KIT expression in pediatric pilocytic astrocytoma (A) and ependymoma
(B). The box plots show the 10th, 25th, 50th (median), 75th and 90th
percentiles.
Table 3. Tumor endothelial cell expression of KIT, phosphorylated KIT, SCF and VEGFR-2 in 84 pediatric brain tumors. Abbreviations: N = number
of cases; SCF = stem cell factor; VEGFR-2 = vascular endothelial cell growth factor receptor-2; PNET = primitive neuroectodermal tumor;
DNT = dysembryoblastic neuroepithelial tumor; SEGA = subependymal giant cell astrocytoma; PXA = pleomorphic xanthoastrocytoma.
Histological diagnosis N Age or median
age (range)
KIT phospho-KIT SCF VEGFR-2
-/+/++/+++ -/+/++/+++ -/+/++/+++ -/+/++/+++
Pilocytic astrocytoma 35 10 (0–18) 12/10/6/7 16/8/4/6* 24/7/0/0* 26/5/0/0*
Ependymoma 11 4 (0–17) 2/3/5/1 1/5/2/3 9/2/0/0 9/1/1/0*
Medulloblastoma 12 9 (1–20) 7/4/1/0 4/5/2/0* 10/0/0/0* 3/4/0/0*
DNT 7 12 (6–17) 5/2/0/0 0/5/2/0 7/0/0/0 7/0/0/0*
Ganglioglioma 4 11.5 (8–19) 4/0/0/0 3/1/0/0 4/0/0/0 3/0/0/0*
Craniopharyngioma 3 17 (10–19) 1/0/0/0* 3/0/0/0 1/0/0/0* 0/0/0/0*
Astrocytoma 1 17 (17) 1/0/0/0 0/1/0/0 1/0/0/0 0/1/0/0
SEGA 2 12 (8–16) 2/0/0/0 1/1/0/0 2/0/0/0 2/0/0/0
Anaplastic astrocytoma 2 9 (7–11) 1/1/0/0 1/0/1/0 2/0/0/0 1/1/0/0
Chroid plexus papilloma 2 1.5 (0–3) 1/1/0/0 2/0/0/0 2/0/0/0 1/1/0/0
Oligodendroglioma 2 13 (7–19) 1/0/0/0* 1/1/0/0 2/0/0/0 2/0/0/0
Oligoastrocytoma 1 19 1/0/0/0 1/0/0/0 1/0/0/0 1/0/0/0
PXA 1 15 1/0/0/0 1/0/0/0 1/0/0/0 1/0/0/0
PNET 1 2 1/0/0/0 0/1/0/0 1/0/0/0 1/0/0/0
Total 84 10 (0–20) 40/21/12/8 34/28/11/9 67/9/0/0 56/13/1/0
*Immunostaining was not informative, or a representative sample tissue was not available in one or more cases.
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HIF-1a was present in the perinecrotic tumor cells at a faint or
moderate intensity in all these tumors. Four out of the ﬁve ependy-
momas with perinecrotic HIF-1a expression showed moderate
(++) expression of KIT in tumor endothelial cells.
KIT and phosphorylated KIT expression in
normal pediatric and fetal tissues
Since tumor endothelial cell KIT and phosphorylated KIT tended
to be more common in young children with pilocytic astrocytoma
or ependymoma, we examined whether endothelial cell KIT
expression might be present in the normal blood vessel endothelia
duringthefetallifeandinyoungchildren.Strong(+++)endothelial
cell KIT expression was detected in the lung alveolar wall capillar-
ies of one 23-week-old fetus.Weak (+) KIT expression was present
in endothelial cells of the small intestine in a 18-week-old fetus,
and in endothelial cells of the brain, lymph nodes, adipose tissue
and spleen of a 40-week-old fetus. Weak KIT expression was
detected also in the brain endothelial cells of a 3-year-old child.
Moderate (++) expression of phosphorylated KIT was present in
the endothelial cells of the small intestine in the 18-week-old
fetuses, and brain endothelial cells showed moderate expression of
phosphorylated KIT in a 18-week-old fetus and strong expression
ina40-week-oldfetus.WhenKITandphosphorylatedKITexpres-
sion were evaluated in the cerebral cortex tissues obtained form
Table 4. Tumor cell expression of KIT,
phosphorylated KIT, SCF and VEGFR-2 in 84
pediatric brain tumors. Abbreviations:
N = number of cases; SCF = stem cell factor;
VEGFR-2 = vascular endothelial cell growth
factor receptor-2; PNET = primitive
neuroectodermal tumor;
DNT = dysembryoblastic neuroepithelial
tumor; SEGA = subependymal giant cell
astrocytoma; PXA = pleomorphic
xanthoastrocytoma.
Histological diagnosis N KIT phospho-KIT SCF VEGFR-2
-/+/++/+++ -/+/++/+++ -/+/++/+++ -/+/++/+++
Pilocytic astrocytoma 35 29/6/0/0 30/4/0/0* 24/6/1/0* 10/15/6/0*
Ependymoma 11 9/2/0/0 7/3/1/0 8/3/0/0 5/4/2/0
Medulloblastoma 12 7/5/0/0 8/3/0/0* 9/1/0/0* 6/1/0/0*
DNT 7 6/0/1/0 6/1/0/0 7/0/0/0 7/0/0/0
Ganglioglioma 4 2/2/0/0 4/0/0/0 2/2/0/0 3/0/0/0*
Craniopharyngioma 3 0/3/0/0 3/0/0/0 1/0/0/0* 3/0/0/0
Astrocytoma 1 1/0/0/0 1/0/0/0 1/0/0/0 1/0/0/0
SEGA 2 1/1/0/0 1/1/0/0 1/1/0/0 1/1/0/0
Anaplastic astrocytoma 2 2/0/0/0 2/0/0/0 2/0/0/0 0/2/0/0
Chroid plexus papilloma 2 0/2/0/0 2/0/0/0 2/0/0/0 2/0/0/0
Oligodendroglioma 2 0/1/0/0* 2/0/0/0 1/1/0/0 1/0/1/0
Oligoastrocytoma 1 1/0/0/0 1/0/0/0 1/0/0/0 1/0/0/0
PXA 1 1/0/0/0 1/0/0/0 1/0/0/0 0/0/0/0*
PNET 1 0/1/0/0 0/1/0/0 0/1/0/0 0/1/0/0
Total 84 59/23/1/0 68/13/1/0 60/15/1/0 40/24/9/0
*Immunostaining was not informative, or a representative tissue sample was not available in one or
more cases.
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CD
Figure 3. Ependymoma showing strong (+++)
endothelial cell KIT expression in the tumor
vessels (A; original magniﬁcation ¥200, ¥400 in
inset) and in microvascular proliferations (B;
¥200). (C) Ependymoma with strong
expression of phosphorylated KIT in tumor
endothelial cells (¥400). KIT mRNA in tumor
microvessel endothelial cells (D) detected by in
situ hybridization (¥400, arrows).
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neurons (5%) were KIT-positive at each age, but no expression
of phosphorylated KIT was detected, and the endothelial cells
expressed KIT or phospho-KIT in none of the cases. Thus, KIT
expression may occasionally occur in the endothelia of histologi-
cally normal tissues in the fetus and young children.
DISCUSSION
We detected moderate or strongly KIT and phospho-KIT expres-
sion in endothelia of 37% and 35% of pilocytic astrocytomas using
immunohistochemistry, and conﬁrmed presence of KIT mRNA in
tumor microvessel endothelial cells using in situ hybridization.
Expression of KIT in pilocytic astrocytoma may be more frequent
than this, as we did not carry out serial sectioning of the tumors in
order to preserve tissue for possible future diagnostic needs. Pres-
ence of phosphorylated KIT in tumor endothelia suggests that
endothelial KIT is frequently activated, and thus likely binds its
ligand,althoughthelevelofSCFintheendothelialcellsmaysome-
times be below the detection threshold of immunohistochemistry.
KITandphosphorylatedKITwerepresentalsointumorendothelia
of other types of pediatric brain tumors, such as ependymomas and
medulloblastomas, suggesting that adult glioblastomas are not the
only types of brain tumors that may express activated endothelial
cell KIT receptor tyrosine kinase.
A growing body of evidence suggests that SCF signaling via the
KIT receptor is angiogenic. Hypoxic stress activates the transcrip-
tional activity of SCF, which enhances endothelial cell prolifera-
tion in the brain microvasculature both in vivo and in vitro (5, 24).
Hypoxia upregulates HIF-1a and VEGF (19), and activation of
KIT by SCF signaling may also result in expression of HIF-1a
(10).Pilocyticastrocytomasdonotusuallyshowoverttissuenecro-
sis, and the majority of the tumors did not express HIF-1a suggest-
ing that tumor endothelial cell KIT expression may not have been
HIF-1a and hypoxia-mediated. In line with this ﬁnding, marked
expression ofVEGFR-2, a major proangiogenic receptor, was rare
in pilocytic astrocytomas and in most other types of pediatric brain
tumors. Yet, tumor cell expression of VEGFR-2 was associated
with endothelial cell expression of KIT, phosphorylated KIT and
SCF. Taken together, these ﬁndings suggest that endothelial cell
KIT may have a role in angiogenesis of pilocytic astrocytomas and
some other types of juvenile brain tumors.
Intratumoral endothelial cells of pilocytic astrocytomas and
ependymomas showed strong KIT expression when the tumors had
been diagnosed at a young age (at an age less than 10 years),
whereasendothelialcellKITexpressionwasusuallyfaintorabsent
when the diagnosis had been made at an older age (Figure 2).This
ﬁnding suggests that the molecular biology of tumor angiogenesis
of young and older children might not be similar despite similar
tumor histology.To investigate this unexpected ﬁnding further, we
assessed KIT expression in endothelial cells of some histologically
normal fetal tissues, and of brain and non-brain tissues of children.
Histologically normal brain vessel endothelium expressed phos-
phorylated KIT both in an 18-week-old fetus and in a 40-week-old
fetus, and KIT-positive vessels were present in the cerebral cortex
of a 3-year-old child but not in the cerebral cortex tissues of older
children aged 4 to 15 years. Although based on a small number of
tissue samples available, these ﬁndings suggest that KIT and phos-
phorylated KIT are present in histologically normal fetal brain
blood vessel endothelia, and that brain endothelial cell KIT expres-
sion may diminish with age. Thus, presence of KIT and activated
KIT in brain tumor microvessels of young children might reﬂect
KITexpressionintheendothelialcellsofnormalbraintissueinthe
fetus and young children. KIT has been reported to be present in
capillary endothelia of the fetal lungs, placenta and soft tissues
(16). In accordance with these ﬁndings, fetal lung alveolar capil-
lary endothelium showed strong KIT expression in the present
study at the gestational age of 23 weeks, which was no longer
present in a 40-week-old fetus.
Tumor endothelial cell KIT expression is frequent in adult glio-
blastomas (21). Glioblastomas are generally rapidly proliferating
and highly lethal brain tumors, which typically contain tumor
necrosis and have hypoxia-driven active tumor angiogenesis. Glio-
blastomas frequently show SCF and HIF-1a expression at the peri-
necrotic tumor regions (21). Endothelial cell KIT expression is
frequentalsoinclear-cellrenalcellcarcinomas,whereHIF-1aand
VEGFR-mediated molecular mechanisms likely have an important
role in tumor pathogenesis (22). Further studies are needed to
investigateassociationsbetweentumornecrosis,histologicalgrade
and endothelial cell KIT expression in different types of human
cancer, and the related molecular biological mechanisms.
Microvascular proliferations are considered a hallmark of glio-
blastomas.Thesepeculiarvascularstructuresconsistofendothelial
cells lining the vessel lumen and abluminal cells expressing
smooth muscle antigens but not endothelial markers (4, 26). In this
series, anaplastic ependymomas showed microvascular prolifera-
tions that were morphologically similar to those found in glioblas-
tomas. These proliferations expressed KIT and phosphorylated
KIT both in endothelial and abluminal cells.
We conclude that KIT is commonly present in the endothelial
cells of brain tumors in children. Endothelial cell KIT is often
phosphorylated suggesting that it is activated. KIT and phosphory-
lated KIT can be detected also in fetal brain microvessel endothe-
lial cells and in endothelial cells of histologically normal brain
tissueofyoungchildren.Inpilocyticastrocytomas,endothelialcell
KIT expression is associated with a young age at the time of the
diagnosis, and with tumor cell expression of KIT, phosphorylated
KIT, and VEGFR-2. The SCF and KIT-mediated signaling may be
important in tumor angiogenesis of pilocytic astrocytomas and
some other types of juvenile brain tumors.
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